Methods of Using Rapid-Onset Selective Serotonin Reuptake Inhibitors for Treating Sexual Dysfunction

Abstract

Methods for the prevention, treatment, or management of sexual dysfunction, such as premature ejaculation, by administering to a patient in need of therapy a therapeutically effective amount of a rapid-onset selective serotonin reuptake inhibitor on an as-needed basis shortly before sexual activity.

What is claimed is: 
     
         1 . A method of treating or managing sexual dysfunction in a mammal in need of treatment comprising administering on an as-needed basis to the mammal an amount of a rapid-onset selective serotonin reuptake inhibitor that is therapeutically effective in the absence of a priming dose. 
     
     
         2 . The method of  claim 1 , wherein the mammal is a human male. 
     
     
         3 . The method of  claim 1 , wherein the rapid-onset selective serotonin reuptake inhibitor is short acting. 
     
     
         4 . The method of  claim 1 , wherein the rapid-onset selective serotonin reuptake inhibitor is delivered in a rapid release formulation. 
     
     
         5 . The method of  claim 1 , comprising the additional step of administering a therapeutically effective amount of a second therapeutic agent for treating or managing a sexual dysfunction. 
     
     
         6 . A method of treating or managing sexual dysfunction in a mammal in need of such treatment comprising administering on an as-needed basis to the mammal a therapeutically effective amount of dapoxetine or a pharmaceutically acceptable salt thereof. 
     
     
         7 . The method of  claim 6 , wherein the mammal is a human male. 
     
     
         8 . The method of  claim 6 , comprising the additional step of administering a therapeutically effective amount of a second therapeutic agent for treating or managing sexual dysfunction. 
     
     
         9 . The method according to  claim 6 , wherein the therapeutically effective amount of dapoxetine is from about 0.001 mg to about 350 mg. 
     
     
         10 . The method of  6 , wherein the therapeutically effective amount of dapoxetine or its pharmaceutically acceptable salt is from about 0.01 mg to about 200 mg. 
     
     
         11 . The method of  6 , wherein the therapeutically effective amount of dapoxetine or its pharmaceutically acceptable salt is from about 0.1 mg to about 120 mg. 
     
     
         12 . The method of  claim 11 , wherein dapoxetine or its pharmaceutically acceptable salt is administered orally. 
     
     
         13 . The method of  claim 12 , wherein dapoxetine or its pharmaceutically acceptable salt is administered in an solid oral dosage form. 
     
     
         14 . The method of  claim 13 , wherein dapoxetine or its pharmaceutically acceptable salt is administered as a tablet or a capsule. 
     
     
         15 . The method of  claim 6 , wherein dapoxetine or its pharmaceutically acceptable salt is delivered as a rapid release formulation.